The Senate Finance Committee has concluded its 18 month investigation looking into the marketing and pricing of Gilead Sciences’ Hepatitis C drugs Sovaldi and Harvoni. The investigation finds that the marketing and pricing of the two drugs was unsurprisingly, profit driven. Furthermore, the pricing of Sovaldi was intended to set the stage for the price of its successor, Harvoni. The link to the article gives the highlights of the strategy along with some interesting quotes from Gilead Sciences’ executives. The second link is to the official press release and full report.